Advanced search
Publication Cover
Journal of Medical Economics Volume 20, 2017 - Issue 9
Submit an article Journal homepage
1,138
Views
24
CrossRef citations to date
0
Altmetric
Cardiovascular

Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting

Jay LinNovosys Health, Green Brook, NJ, USA; Correspondence[email protected]
,
Jeffrey TrocioPfizer, Inc., New York, NY, USA;
,
Kiran GuptaBristol-Myers Squibb, Lawrenceville, NJ, USA
,
Jack MardekianPfizer, Inc., New York, NY, USA;
,
Melissa Lingohr-SmithNovosys Health, Green Brook, NJ, USA;
,
Brandy MengesNovosys Health, Green Brook, NJ, USA;
,
Min YouBristol-Myers Squibb, Lawrenceville, NJ, USA
&
Anagha NadkarniBristol-Myers Squibb, Lawrenceville, NJ, USA
 show all
Pages 952-961 | Received 18 Apr 2017, Accepted 06 Jun 2017, Published online: 22 Jun 2017

Citations (24)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (8)

Gregory J. Fermann, Belinda Lovelace, Mary J. Christoph, Melissa Lingohr-Smith, Jay Lin & Steven B. Deitelzweig. (2020) Major bleed costs of atrial fibrillation patients treated with factor Xa inhibitor anticoagulants. Journal of Medical Economics 23:12, pages 1409-1417.
Read now
Steven Deitelzweig, Amol D. Dhamane, Manuela Di Fusco, Cristina Russ, Lisa Rosenblatt, Melissa Lingohr-Smith & Jay Lin. (2020) Utilization of anticoagulants and predictors of treatment among hospitalized patients with atrial fibrillation in the USA. Journal of Medical Economics 23:12, pages 1389-1400.
Read now
Dejan Milentijevic, Guillaume Germain, François Laliberté, Brahim K. Bookhart, Sean D. MacKnight, Jenkin Tsang & Patrick Lefebvre. (2020) Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US. Journal of Medical Economics 23:11, pages 1365-1374.
Read now
Steven Deitelzweig, Christine L. Baker, Amol D. Dhamane, Jack Mardekian, Oluwaseyi Dina, Lisa Rosenblatt, Cristina Russ, Tayla Poretta, Melissa Lingohr-Smith & Jay Lin. (2020) Comparison of readmissions among hospitalized nonvalvular atrial fibrillation patients treated with oral anticoagulants in the United States. Journal of Drug Assessment 9:1, pages 87-96.
Read now
Amol D. Dhamane, Christine L. Baker, Jigar Rajpura, Jack Mardekian, Oluwaseyi Dina, Cristina Russ, Lisa Rosenblatt, Melissa Lingohr-Smith & Jay Lin. (2019) Continuation with apixaban treatment is associated with lower risk for hospitalization and medical costs among elderly patients. Current Medical Research and Opinion 35:10, pages 1769-1776.
Read now
Ameenathul M. Fawzy, Wang-Yang Yang & Gregory YH. Lip. (2019) Safety of direct oral anticoagulants in real–world clinical practice: translating the trials to everyday clinical management. Expert Opinion on Drug Safety 18:3, pages 187-209.
Read now
Henry J. Henk, Feng Cao, Kenneth Tuell, Kwanza Price, Prianka Singh, Jack Mardekian, Kevin Odell, Chad Patel, Wilson Tan, George H. Sands, Shalabh Singhal, Jeffrey Trocio & Lien Vo. (2018) Treatment and discharge patterns among patients hospitalized with non-valvular atrial fibrillation transitioning from the inpatient to outpatient setting. Current Medical Research and Opinion 34:3, pages 539-546.
Read now
Adam Ioannou, Irene Tsappa, Sofia Metaxa & Constantinos G Missouris. (2017) Non-valvular atrial fibrillation: impact of apixaban on patient outcomes. Patient Related Outcome Measures 8, pages 121-131.
Read now

Articles from other publishers (16)

Michael Situ, Ute I. Schwarz, Guangyong Zou, Eric McArthur, Richard B. Kim, Amit X. Garg & Sisira Sarma. (2023) Does prescribing apixaban or rivaroxaban versus warfarin for patients diagnosed with atrial fibrillation save health system costs? A multivalued treatment effects analysis. The European Journal of Health Economics.
Crossref
Tania Ahuja, Veronica Raco, Sharonlin Bhardwaj & David Green. (2023) To Measure or Not to Measure: Direct Oral Anticoagulant Laboratory Assay Monitoring in Clinical Practice. Advances in Hematology 2023, pages 1-7.
Crossref
Benjamin J. R. Buckley, Deirdre A. Lane, Peter Calvert, Juqian Zhang, David Gent, C. Daniel Mullins, Paul Dorian, Shun Kohsaka, Stefan H. Hohnloser & Gregory Y. H. Lip. (2022) Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine 11:13, pages 3788.
Crossref
Souad Moudallel, Sven Laere, Pieter Cornu, Alain Dupont & Stephane Steurbaut. (2022) Assessment of adherence, treatment satisfaction and knowledge of direct oral anticoagulants in atrial fibrillation patients. British Journal of Clinical Pharmacology 88:5, pages 2419-2429.
Crossref
Zhiyan Liu, Lingyue Ma, Hanxu Zhang, Guangyan Mu, Qiufen Xie, Shuang Zhou, Zining Wang, Zhe Wang, Kun Hu, Yanjun Gong, Jie Jiang, Qian Xiang & Yimin Cui. (2021) Comparison of non‐vitamin K antagonist oral anticoagulants on bleeding and thrombosis. Journal of Clinical Pharmacy and Therapeutics 46:6, pages 1729-1742.
Crossref
Wengen Zhu, Zi Ye, Shilan ChenDexi Wu, Jiangui HeYugang DongGregory Y.H. Lip & Chen Liu. (2021) Comparative Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients. Stroke 52:4, pages 1225-1233.
Crossref
Eveline M Bunge, Ben van Hout, Sylvia Haas, Georgios Spentzouris & Alexander Cohen. (2021) Critical appraisal and issues regarding generalisability of comparative effectiveness studies of NOACs in atrial fibrillation and their relation to clinical trial data: a systematic review. BMJ Open 11:2, pages e042024.
Crossref
Steven B. Deitelzweig, Belinda Lovelace, Mary Christoph, Melissa Lingohr-Smith, Jay Lin & Gregory J. Fermann. (2020) Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA. Advances in Therapy 37:9, pages 3942-3953.
Crossref
Jessica Franchino‐Elder, Adrienne Gilligan, Xue Song, Briain O Hartaigh, Caroline Henriques, Amy Sainski‐Nguyen & Cheng Wang. (2020) Comparison of healthcare costs among patients with non‐valvular atrial fibrillation treated with warfarin who switched to a novel oral anticoagulant. Journal of Pharmaceutical Health Services Research 11:2, pages 133-140.
Crossref
Alpesh AminAllison KeshishianJeffrey TrocioOluwaseyi DinaHannah LeLisa RosenblattXianchen LiuJack MardekianQisu ZhangOnur BaserAnagha NadkarniLien Vo. (2020) A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population. Journal of Managed Care & Specialty Pharmacy 26:5, pages 639-651.
Crossref
Antonios Douros, Madeleine Durand, Carla M. Doyle, Sarah Yoon, Pauline Reynier & Kristian B. Filion. (2019) Comparative Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis of Observational Studies. Drug Safety 42:10, pages 1135-1148.
Crossref
Christine L. Baker, Amol D. Dhamane, Jigar Rajpura, Jack Mardekian, Oluwaseyi Dina, Cristina Russ, Lisa Rosenblatt, Melissa Lingohr-Smith & Jay Lin. (2019) Switching to Another Oral Anticoagulant and Drug Discontinuation Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Different Direct Oral Anticoagulants. Clinical and Applied Thrombosis/Hemostasis 25, pages 107602961987024.
Crossref
Christine L. Baker, Amol D. Dhamane, Jack Mardekian, Oluwaseyi Dina, Cristina Russ, Lisa Rosenblatt, Melissa Lingohr-Smith, Brandy Menges, Jay Lin & Anagha Nadkarni. (2018) Comparison of Drug Switching and Discontinuation Rates in Patients with Nonvalvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States. Advances in Therapy 36:1, pages 162-174.
Crossref
Angela LowensternSana M. Al-KhatibLauren SharanRanee ChatterjeeNancy M. Allen LaPointeBimal ShahEthan D. BorreGiselle RaitzAdam GoodeRoshini YapaJ. Kelly DavisKathryn LallingerRobyn SchmidtAndrzej S. KosinskiGillian D. Sanders. (2018) Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation. Annals of Internal Medicine 169:11, pages 774.
Crossref
Alpesh AminAllison KeshishianJeffrey TrocioOluwaseyi DinaHannah LeLisa RosenblattXianchen LiuJack MardekianQisu ZhangOnur BaserAnagha NadkarniLien Vo. (2018) A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population. Journal of Managed Care & Specialty Pharmacy 24:9, pages 911-920.
Crossref
Steve Deitelzweig, Xuemei Luo, Kiran Gupta, Jeffrey Trocio, Jack Mardekian, Tammy Curtice, Patrick Hlavacek, Melissa Lingohr-Smith, Brandy Menges & Jay Lin. (2018) All-Cause, Stroke/Systemic Embolism–, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants. Clinical and Applied Thrombosis/Hemostasis 24:4, pages 602-611.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.